The Absolute Effect / Evidence index
Advanced / Metastatic · Phase III open-label randomized; N=455; first-line PD-L1 TPS <1% nonsquamous NSCLC without targetable alterations. Sacituzumab tirumotecan + pembrolizumab vs platinum-pemetrexed + pembrolizumab. Primary endpoint BICR PFS. · Median PFS 15.0 vs 5.7 months
OptiTROP-Lung06
Clinical question: Does sacituzumab tirumotecan plus pembrolizumab improve PFS over platinum-pemetrexed plus pembrolizumab in first-line PD-L1-negative advanced nonsquamous NSCLC?
Median PFS 15.0 vs 5.7 months; HR 0.49 (95% CI 0.36–0.65; P<0.001). ORR 50.2% vs 47.3%; OS immature (HR 0.58). · Registry:
Design, population and treatment
Phase III open-label randomized; N=455; first-line PD-L1 TPS <1% nonsquamous NSCLC without targetable alterations. Sacituzumab tirumotecan + pembrolizumab vs platinum-pemetrexed + pembrolizumab. Primary endpoint BICR PFS.
Key efficacy outcome
Grade ≥3 AEs 47.6% vs 60.6%; stomatitis with sacituzumab tirumotecan predominantly grade 1–2.
Safety and absolute effect
Median PFS (months)
https://www.nejm.org/doi/full/10.1056/NEJMoa2611280
Interpretation and limitations
Current-practice context · 14 November 2026: Primary publication/abstract and trial identifier checked. Guideline-level current-practice mapping was not established in this publication-led batch; no NCCN citation provenance is claimed. Where detailed QoL, follow-up or toxicity data were not present in the retrieved abstract, they are not inferred.